Take a look at our previous reports:

Welcome to our
Q3 Report 2022
scroll for more
Letter from our CEO

Guided by our purpose to bring transformational medicines to patients around the world to help them live longer and healthier lives, we are today announcing our Forward, Faster strategy to accelerate growth and value creation by reshaping the way we innovate and operate.

Dr. Paul Stoffels, CEO

We are very proud that Jyseleca, our first marketed medicine, continues to perform very well with a growing European base and a solid €60.5 million in net sales as of 30 September. As a result, we increase our 2022 net sales guidance to €80-€90 million.

Bart Filius, President, COO & CFO

Financial highlights

Group revenues 410.2 million
Jyseleca net sales
€60.5 million
Cash position 4362.1 million
Deferred income 2052.7 million
R&D expenditure 364.1 million